Currently, there are 106.09M common shares owned by the public and among those 100.30M shares have been available to trade.
Insiders at the company have transacted a total of 61 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 22 of these insider trades were purchases, accounting for 205,400 shares. Insider sales of the common stock occurred on 39 occasions, with total insider shares sold totaling 117,532 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 75.64, up 0.33%. The company’s stock has a 5-day price change of 0.60% and 48.15% over the past three months. PCVX shares are trading 19.84% year to date (YTD), with the 12-month market performance up to 74.41% higher. It has a 12-month low price of $34.11 and touched a high of $76.72 over the same period. PCVX has an average intraday trading volume of 846.18K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 6.81%, 16.85%, and 41.28% respectively.
Institutional ownership of Vaxcyte Inc (NASDAQ: PCVX) shares accounts for 93.66% of the company’s 106.09M shares outstanding.
It has a market capitalization of $7.98B and a beta (3y monthly) value of 0.92. The earnings-per-share (ttm) stands at -$3.34. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.60% over the week and 3.90% over the month.
Analysts forecast that Vaxcyte Inc (PCVX) will achieve an EPS of $Pacira BioSciences, Inc. for the current quarter, $29.08 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Vaxcyte, Inc. while analysts give the company a high EPS estimate of $Icosavax, Inc. Comparatively, EPS for the current quarter was $PCVVX a year ago. Earnings per share for the fiscal year are expected to increase by 0.48%, and -23.50% over the next financial year.
Looking at the support for the PCVX, a number of firms have released research notes about the stock. Mizuho stated their Buy rating for the stock in a research note on December 07, 2023, with the firm’s price target at $69.
